<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723186</url>
  </required_header>
  <id_info>
    <org_study_id>MT1002-II-C01</org_study_id>
    <nct_id>NCT04723186</nct_id>
  </id_info>
  <brief_title>MT1002 Phase II Study in ACS Patients With PCI</brief_title>
  <official_title>Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing MT1002 in Patients Undergoing PCI Due to Acute Coronary Syndrome With NSTEMI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaanxi Micot Technology Limited Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaanxi Micot Technology Limited Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels&#xD;
      of MT1002 in patients undergoing PCI due to ACS with NSTEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MT1002 is a novel bispecific peptide with properties of a direct thrombin inhibitor and a&#xD;
      glycoprotein IIb/IIIa inhibitor.&#xD;
&#xD;
      Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve&#xD;
      target ACT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Sequential-Dose Escalation/De-escalation Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safe and well tolerated dose of MT1002 in patients.</measure>
    <time_frame>30 days</time_frame>
    <description>General safety, including vital signs, physical examination, electrocardiogram, laboratory assessments, adverse events, MACE within 30 days, and major bleeding events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the anti-coagulation effect of MT1002</measure>
    <time_frame>30 days</time_frame>
    <description>By activated partial thromboplastin time (aPTT) and activated clotting time (ACT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the anti-platelet effect of MT1002</measure>
    <time_frame>30 days</time_frame>
    <description>By inhibition of platelet aggregation (IPA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>MT1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) via IV access prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT1002</intervention_name>
    <description>Monotherapy of MT1002, 3 doses via intravenous (IV) + infusion</description>
    <arm_group_label>MT1002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting within 24 hours from the onset of symptoms of cardiac ischemia&#xD;
&#xD;
          -  Diagnosed with NSTEMI defined as new or presumably new ST-segment depression of at&#xD;
             least 1 mm in 2 contiguous leads, T-wave inversion more than 3 mm, or any dynamic ST&#xD;
             shifts, or elevated troponin I higher than upper limit of normal (ULN), T, or CK-MB&#xD;
             consistent with the universal definition of MI, and admission within 24 hours of&#xD;
             symptom onset&#xD;
&#xD;
          -  Indication for early PCI as per international or local guidelines&#xD;
&#xD;
          -  Ability to understand and willing to give written informed consent. Signed informed&#xD;
             consent form before any study related activities.&#xD;
&#xD;
               -  Women of childbearing potential must have a negative pregnancy test or be&#xD;
                  post-menopausal for at least 1 year before enrollment or be permanently&#xD;
                  sterilized since ≥6 weeks (ie, documented hysterectomy, bilateral salpingectomy,&#xD;
                  or bilateral oophorectomy). Females of childbearing potential and males with&#xD;
                  partners of childbearing potential must be using effective contraception if they&#xD;
                  become sexually active from the time of consent to 90 days after the MT1002&#xD;
                  infusion day (ie, any double combination of male or female condom with&#xD;
                  spermicidal gel, diaphragm, sponge, or cervical cap with spermicidal gel). Women&#xD;
                  who are breastfeeding are excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock or prolonged cardiopulmonary resuscitation (CPR)&#xD;
&#xD;
          -  Active bleeding, bleeding diathesis, coagulopathy&#xD;
&#xD;
          -  Any history of intracranial bleeding or structural abnormalities (intracerebral mass,&#xD;
             aneurysm, arteriovenous malformation [AVM])&#xD;
&#xD;
          -  Prior transient ischemic attack, prior stroke within 12 months&#xD;
&#xD;
          -  Index MI is STEMI or new left bundle branch block&#xD;
&#xD;
          -  The following planned procedures within 30 days after enrollment: staged PCI, CABG,&#xD;
             valve surgery, or additional invasive procedures&#xD;
&#xD;
          -  Pre-existing atrial fibrillationand prolonged QTc (470ms in men, 480ms in women)&#xD;
&#xD;
          -  Anticipated requirement for oral anticoagulants before Day 30 9. CRUSADE (Can Rapid&#xD;
             risk stratification of Unstable angina patients Suppress ADverse outcomes with Early&#xD;
             implementation of the American College of Cardiology/American Heart Association&#xD;
             [ACC/AHA] Guidelines) bleeding risk score &gt;40&#xD;
&#xD;
          -  Suspected aortic dissection&#xD;
&#xD;
          -  History of gastrointestinal or genitourinary bleeding within the previous 3 months&#xD;
&#xD;
          -  Refusal to receive blood transfusion if needed during the study&#xD;
&#xD;
          -  Major surgery in the last 6 months&#xD;
&#xD;
          -  History of heparin-induced thrombocytopenia and bleeding diathesis&#xD;
&#xD;
          -  Severe uncontrolled hypertension, defined as a systolic blood pressure &gt; 180 mm Hg and&#xD;
             diastolic blood pressure &gt; 100 mm Hg despite 1 hour of adequate treatment&#xD;
&#xD;
          -  Prior or planned administration of thrombolytics, glycoprotein IIb/IIIa inhibitors,&#xD;
             bivalirudin, or fondaparinux for the index MI. Subcutaneous injections of&#xD;
             unfractionated heparin and low molecular weight heparin are allowed up to 4 hours and&#xD;
             8 hours, respectively, before study drug.&#xD;
&#xD;
          -  Known relevant hematological deviations: hemoglobin (male) &lt; 11 g/dL, hemoglobin&#xD;
             (female) &lt; 10 g/dL, hematocrit &lt; 35%, platelet count &lt; 100,000 cells/μL&#xD;
&#xD;
          -  Use of Coumadin derivatives within the last 7 days&#xD;
&#xD;
          -  Chronic therapy with non-steroidal anti-inflammatory drugs (NSAIDs; except aspirin),&#xD;
             cyclooxegenase (COX)-2 inhibitors, prasugrel, ticagrelor within one month before&#xD;
             screening&#xD;
&#xD;
          -  Known malignancies or other comorbid conditions with life expectancy &lt; 1 year that may&#xD;
             result in protocol noncompliance&#xD;
&#xD;
          -  Known severe liver disease (aspartate aminotransferase [AST], alanine aminotransferase&#xD;
             [ALT] &gt; 3 × ULN)&#xD;
&#xD;
          -  Known positive serology for hepatitis B &amp; C, HIV screen&#xD;
&#xD;
          -  Known chronic kidney disease with glomerular filtration rate &lt;30 mL/min and/or&#xD;
             dialysis&#xD;
&#xD;
          -  Known allergy or intolerance to aspirin, clopidogrel, bivalirudin, unfractionated&#xD;
             heparin, P2Y12 antagonists, or contrast&#xD;
&#xD;
          -  Previous enrollment in this trial&#xD;
&#xD;
          -  Inability to fully cooperate with the study protocol&#xD;
&#xD;
          -  Any other medical or psychiatric condition that in the Investigator's judgment&#xD;
             precludes participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruben Zhao, MD</last_name>
    <phone>+86 18001098786</phone>
    <email>zhaolibin@micot.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sachin Ojha</last_name>
    <phone>+61 439949954</phone>
    <email>Sachin.Ojha@premier-research.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jay Traverse</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Traverse, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nicholas M Burke, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACS, PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

